Loading...

Heat Biologics

DB:1HB1
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1HB1
DB
$39M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient’s immune system against cancer in the United States. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • Heat Biologics has significant price volatility in the past 3 months.
1HB1 Share Price and Events
7 Day Returns
2.3%
DB:1HB1
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
7.5%
DB:1HB1
-10.2%
DE Biotechs
-6%
DE Market
1HB1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Heat Biologics (1HB1) 2.3% -4.3% -12.4% 7.5% -82% -97.4%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 1HB1 outperformed the Biotechs industry which returned -10.2% over the past year.
  • 1HB1 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
1HB1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Heat Biologics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Heat Biologics. This is due to cash flow or dividend data being unavailable. The share price is €1.043.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Heat Biologics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Heat Biologics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1HB1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.90
NasdaqCM:HTBX Share Price ** NasdaqCM (2019-04-18) in USD $1.14
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Heat Biologics.

DB:1HB1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:HTBX Share Price ÷ EPS (both in USD)

= 1.14 ÷ -0.90

-1.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Heat Biologics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Heat Biologics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Heat Biologics's expected growth come at a high price?
Raw Data
DB:1HB1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
4.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Heat Biologics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Heat Biologics's assets?
Raw Data
DB:1HB1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.93
NasdaqCM:HTBX Share Price * NasdaqCM (2019-04-18) in USD $1.14
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:1HB1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:HTBX Share Price ÷ Book Value per Share (both in USD)

= 1.14 ÷ 0.93

1.22x

* Primary Listing of Heat Biologics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Heat Biologics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Heat Biologics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Heat Biologics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Heat Biologics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
4.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Heat Biologics expected to grow at an attractive rate?
  • Heat Biologics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Heat Biologics's earnings growth is positive but not above the Germany market average.
  • Heat Biologics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1HB1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1HB1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 4.8%
DB:1HB1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 45.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1HB1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1HB1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 165 33 1
2022-12-31 11 -41 2
2021-12-31 0 -24 2
2020-12-31 1 -22 3
2019-12-31 7 -21 2
DB:1HB1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 6 -22 -16
2018-09-30 4 -13 -14
2018-06-30 3 -13 -13
2018-03-31 2 -7 -12
2017-12-31 2 -6 -12
2017-09-30 1 -12 -12
2017-06-30 1 -10 -11
2017-03-31 0 -12 -11
2016-12-31 0 -14 -13
2016-09-30 0 -16 -16
2016-06-30 -18 -19
2016-03-31 -18 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Heat Biologics's earnings are expected to grow by 4.8% yearly, however this is not considered high growth (20% yearly).
  • Heat Biologics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1HB1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Heat Biologics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1HB1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.55 0.55 0.55 1.00
2022-12-31 -0.93 -0.90 -0.95 2.00
2021-12-31 -0.62 -0.38 -0.86 2.00
2020-12-31 -0.64 -0.37 -0.90 3.00
2019-12-31 -0.65 -0.57 -0.72 2.00
DB:1HB1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.90
2018-09-30 -1.15
2018-06-30 -1.80
2018-03-31 -2.80
2017-12-31 -3.08
2017-09-30 -3.98
2017-06-30 -4.34
2017-03-31 -5.08
2016-12-31 -7.15
2016-09-30 -11.43
2016-06-30 -17.62
2016-03-31 -24.37

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Heat Biologics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Heat Biologics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Heat Biologics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Heat Biologics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Heat Biologics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Heat Biologics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Heat Biologics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Heat Biologics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Heat Biologics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Heat Biologics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1HB1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 5.79 -15.73 7.03
2018-09-30 4.35 -13.93 6.20
2018-06-30 2.98 -13.01 5.80
2018-03-31 2.25 -12.18 6.02
2017-12-31 1.52 -11.84 5.77
2017-09-30 1.03 -12.18 5.50
2017-06-30 0.78 -11.50 5.13
2017-03-31 0.37 -11.20 4.63
2016-12-31 0.34 -12.57 4.14
2016-09-30 0.22 -15.59 4.45 -1.77
2016-06-30 -19.16 4.57 -1.09
2016-03-31 -20.95 4.38 -0.50
2015-12-31 -20.30 4.66
2015-09-30 -17.42 4.38 2.20
2015-06-30 -15.23 4.25 2.57
2015-03-31 -13.37 4.37 2.83
2014-12-31 -11.79 4.08 2.86
2014-09-30 -10.24 3.83 3.04
2014-06-30 -9.57 3.75 2.99
2014-03-31 -8.34 3.18 2.83
2013-12-31 -9.07 2.43 2.74
2013-09-30 0.00 -7.76 1.82 2.43
2013-06-30 0.00 -6.00 1.31 1.68
2013-03-31 0.00 -5.02 1.23 1.17
2012-12-31 0.00 -2.40 1.19 0.90
2012-09-30 0.00 -2.22 1.07 1.84

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Heat Biologics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Heat Biologics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Heat Biologics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Heat Biologics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Heat Biologics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Heat Biologics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Heat Biologics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Heat Biologics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Heat Biologics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Heat Biologics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Heat Biologics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Heat Biologics Company Filings, last reported 3 months ago.

DB:1HB1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 30.24 0.00 27.72
2018-09-30 22.43 0.00 20.96
2018-06-30 25.45 0.00 24.66
2018-03-31 5.84 0.00 8.96
2017-12-31 5.78 0.00 9.76
2017-09-30 6.63 0.00 4.29
2017-06-30 9.01 0.00 8.35
2017-03-31 10.11 0.00 11.13
2016-12-31 6.84 0.00 7.84
2016-09-30 5.14 2.88 8.46
2016-06-30 1.12 5.16 7.12
2016-03-31 3.97 5.94 11.84
2015-12-31 2.49 6.75 11.63
2015-09-30 8.75 4.89 14.95
2015-06-30 13.95 5.01 19.36
2015-03-31 18.55 2.73 21.05
2014-12-31 11.03 2.71 14.41
2014-09-30 14.42 1.19 15.40
2014-06-30 17.01 0.00 16.85
2014-03-31 19.64 0.00 19.44
2013-12-31 21.72 0.00 21.86
2013-09-30 23.64 0.00 23.58
2013-06-30 1.30 0.73 3.02
2013-03-31 2.72 1.39 4.89
2012-12-31 -1.42 0.92 0.01
2012-09-30 -0.78 0.52 0.13
  • Heat Biologics has no debt.
  • Heat Biologics had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Heat Biologics has sufficient cash runway for 1.2 years based on current free cash flow.
  • Heat Biologics has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -8.8% each year.
X
Financial health checks
We assess Heat Biologics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Heat Biologics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Heat Biologics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Heat Biologics dividends.
If you bought €2,000 of Heat Biologics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Heat Biologics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Heat Biologics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1HB1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1HB1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Heat Biologics has not reported any payouts.
  • Unable to verify if Heat Biologics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Heat Biologics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Heat Biologics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Heat Biologics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Heat Biologics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Heat Biologics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Heat Biologics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jeff Wolf
COMPENSATION $963,763
AGE 55
TENURE AS CEO 10.7 years
CEO Bio

Mr. Jeffrey Alan Wolf, also known as Jeff, J.D., is the Chief Executive Officer and President of Heat Biologics, Inc. since August 2008 and served as its Treasurer and Secretary. Mr. Wolf Co-Founded Pelican Therapeutics, Inc in 2009. Mr. Wolf served as the Chief Financial Officer of Heat Biologics, Inc. He founded Heat Biologics in August 2008. Mr. Wolf founded and served as the Chief Executive Officer of GenerationOne, Inc. He founded Conversion Technologies International, Inc. He co-founded and served as Managing Partner at Sunrock Equity Partners and Sunrock Ventures, L.P. He was the Founding Partner of Seed-One Ventures, LLC, a venture capital group focused on seed-stage technology-based investments. From June 1997 to March 2011, he has served as Managing Director at Seed-One Ventures, LLC a medically-focused venture capital firm. Mr. Wolf co-founded Sensatex Inc., and served as its Chief Executive Officer. He was also employed at NetLive Communications Inc. From November 1994 to December 1995, he served as the Head of Berenson Minella Ventures. From July 1991 to November 1994, he served as Vice President and Managing Director at The Castle Group, Ltd. He served as a Vice President at D.H. Blair & Co., Inc. Mr. Wolf co-founded Generation Mobile Inc., Tyrx Pharma Inc., and Lindatech Inc. He co-founded Elusys Therapeutics Inc. and served as its Chairman and Chief Executive Officer. He co-founded Xenometrix in February 1994, Avigen, Inc. in February 1994 and Conversion Technologies in February 1994. He was a Managing General Partner at Athena Ventures, LLC. He is the Chairman of Heat Biologics, Inc. since August 2008. He served as Chairman of GenerationOne, Inc. He served as Chairman of TyRx Pharma. He serves as a Director of Pelican Therapeutics, Inc, EluSys Therapeutics Inc., GenerationOne, Inc and BCY LifeSciences Inc. Mr. Wolf has been a Director of Pipex since 2005 and Synthetic Biologics, Inc. since 2006. He served as a Director of Netli Inc., Athena Ventures, LLC, Sensatex Inc and Avigen, Inc. He has board extensive knowledge of the pharmaceutical and biotechnology industries. Having served in senior corporate positions in several biomedical companies, he has a vast knowledge of the industry. Mr. Wolf holds an MBA from Stanford Business School, a J.D. from New York University School of Law and a B.A. degree with honors in Economics from the University of Chicago.

CEO Compensation
  • Jeff's compensation has increased whilst company is loss making.
  • Jeff's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Heat Biologics management team in years:

1.9
Average Tenure
61
Average Age
  • The average tenure for the Heat Biologics management team is less than 2 years, this suggests a new team.
Management Team

Jeff Wolf

TITLE
Founder
COMPENSATION
$964K
AGE
55
TENURE
10.7 yrs

Jeff Hutchins

TITLE
Chief Scientific Officer & COO
COMPENSATION
$547K
AGE
59
TENURE
1.8 yrs

Ann Rosar

TITLE
Consultant
COMPENSATION
$380K
AGE
66
TENURE
0.1 yrs

Robert Jakobs

TITLE
VP of Finance
AGE
63

Justin Stebbing

TITLE
Chief Medical Advisor and Member of Scientific & Clinical Advisory Board

George Peoples

TITLE
Chief Medical Advisor
TENURE
2 yrs
Board of Directors Tenure

Average tenure and age of the Heat Biologics board of directors in years:

5.5
Average Tenure
61.5
Average Age
  • The tenure for the Heat Biologics board of directors is about average.
Board of Directors

Justin Stebbing

TITLE
Chief Medical Advisor and Member of Scientific & Clinical Advisory Board

John Monahan

TITLE
Director
COMPENSATION
$140K
AGE
72
TENURE
9.4 yrs

Jeff Wolf

TITLE
Founder
COMPENSATION
$964K
AGE
55
TENURE
10.7 yrs

Ed Smith

TITLE
Director
COMPENSATION
$131K
AGE
43
TENURE
8.4 yrs

John K. Prendergast

TITLE
Lead Independent Director
COMPENSATION
$349K
AGE
64
TENURE
2.6 yrs

Gary Acton

TITLE
Member of Scientific & Clinical Advisory Board
AGE
59

Llew Keltner

TITLE
Member of Scientific & Clinical Advisory Board
AGE
68

Roger Cohen

TITLE
Member of Scientific & Clinical Advisory Board

Robert Levy

TITLE
Member of Scientific Advisory Board
TENURE
1.5 yrs

Robert Negrin

TITLE
Member of Scientific Advisory Board
TENURE
1.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Heat Biologics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Heat Biologics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient’s immune system against cancer in the United States. The company’s T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb’s nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina.

Details
Name: Heat Biologics, Inc.
1HB1
Exchange: DB
Founded: 2008
$34,537,691
34,071,323
Website: http://www.heatbio.com
Address: Heat Biologics, Inc.
801 Capitola Drive,
Suite 12,
Durham,
North Carolina, 27713,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM HTBX Common Stock Nasdaq Capital Market US USD 24. Jul 2013
DB 1HB1 Common Stock Deutsche Boerse AG DE EUR 24. Jul 2013
Number of employees
Current staff
Staff numbers
30
Heat Biologics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:34
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/08
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.